OXFORD HEALTH NHS FOUNDATION TRUST

Epilepsy Drug Ezogabine Shows Promise as Novel Depression Treatment by Targeting Brain Potassium Channels

- Two recent studies reveal that ezogabine, an FDA-approved epilepsy medication, may effectively treat depression by normalizing hyperactivity in the brain's reward circuitry through KCNQ potassium channel modulation. - Researchers at Mount Sinai found ezogabine reduced abnormal connectivity between reward centers and regions associated with negative thoughts, potentially addressing anhedonia—the inability to experience pleasure—which is often resistant to conventional treatments. - The findings represent a significant advancement in depression treatment, offering a fundamentally different biological approach for patients who don't respond to first-line therapies.